{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Interaction+Study&page=2", "query": { "condition": "Drug Interaction Study", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Interaction+Study&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-04T17:49:44.554Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02568397", "title": "A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Lanabecestat", "type": "DRUG" }, { "name": "Dabigatran etexilate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": "2015-10-31", "completion_date": "2016-01-31", "has_results": true, "last_update_posted_date": "2019-11-01", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02568397" }, { "nct_id": "NCT03442621", "title": "Relacorilant Food Effect Study in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Food-drug Interaction" ], "interventions": [ { "name": "Relacorilant Fasted", "type": "DRUG" }, { "name": "Relacorilant with a high fat breakfast", "type": "DRUG" }, { "name": "Relacorilant with a moderate breakfast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2018-01-16", "completion_date": "2018-03-09", "has_results": false, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03442621" }, { "nct_id": "NCT01769768", "title": "Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "LDE225", "type": "DRUG" }, { "name": "Wafarin", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2013-04", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 13, "location_summary": "Duarte, California • Kansas City, Kansas • Boston, Massachusetts + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT01769768" }, { "nct_id": "NCT04142762", "title": "A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "ABI-H2158", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Ethinyl Estradiol / Levonorgestrel", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "Placebo matching oral contraceptive", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Assembly Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 80, "start_date": "2019-10-18", "completion_date": "2020-01-29", "has_results": false, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04142762" }, { "nct_id": "NCT05692570", "title": "A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-drug Interaction" ], "interventions": [ { "name": "PBI-200 Tablet", "type": "DRUG" }, { "name": "Ritonavir Oral Tablet", "type": "DRUG" }, { "name": "Cobicistat Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pyramid Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 21, "start_date": "2022-09-09", "completion_date": "2022-11-12", "has_results": false, "last_update_posted_date": "2023-01-20", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05692570" }, { "nct_id": "NCT01072175", "title": "Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK2118436", "type": "DRUG" }, { "name": "GSK1120212", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2010-03-26", "completion_date": "2018-02-27", "has_results": true, "last_update_posted_date": "2019-07-05", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01072175" }, { "nct_id": "NCT00546741", "title": "Drug Interaction With Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Male and Female Subjects" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Dapagliflozin + Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 18, "start_date": "2007-11", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2016-12-20", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 1, "location_summary": "Hamilton, New Jersey", "locations": [ { "city": "Hamilton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546741" }, { "nct_id": "NCT00361790", "title": "Aripiprazole and Lexapro Drug Interaction Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 25, "start_date": "2006-08", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-11-08", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00361790" }, { "nct_id": "NCT06945276", "title": "Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "ALG-097558", "type": "DRUG" }, { "name": "Dabigatran", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 51, "start_date": "2025-05-13", "completion_date": "2025-08-01", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06945276" }, { "nct_id": "NCT05895266", "title": "A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "ABBV-903", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2023-06-23", "completion_date": "2023-11-02", "has_results": false, "last_update_posted_date": "2023-11-09", "last_synced_at": "2026-09-04T17:49:44.554Z", "location_count": 1, "location_summary": "Grayslake, Illinois", "locations": [ { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05895266" } ] }